WithdrawnPhase 1NCT04093648

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)

Studying Hepatoblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Baylor College of Medicine
Principal Investigator
Andras Heczey, MD, M.D
Baylor College of Medicine
Intervention
TEGAR T cells(genetic)
Eligibility
1 years · All sexes
Timeline
20202038

Collaborators

The Methodist Hospital Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04093648 on ClinicalTrials.gov

Other trials for Hepatoblastoma

Additional recruiting or active studies for the same condition.

See all trials for Hepatoblastoma

← Back to all trials